#0854 @Official_ASAS & @SPARTAN_Updates revised #axSpA criteria meet targets: Sn 79.5% / Sp 90.4%. Imaging is centr https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg john+RNV2@john… Mon, […]
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed @RheumNow #ACR2025 https://pbs.twimg.com/profile_images/1798008672708169728/8cvULQ3I_normal.jpg john+RNV2@john…
Clinical and Medicare records for more than 40,000 patients seen at U.S. rheumatology clinics in 2021 showed that 43.3% received
(MedPage Today) — CHICAGO — Urgent advice to prescribe alternatives to opioid painkillers doesn’t seem to be getting through to
The most common rheumatic disease reported was rheumatoid arthritis (58%), followed by Sjögren disease (19%). CAM usage was found to
… Rheumatology (ACR) Convergence 2025. A retrospective cohort study was conducted using data from the TriNetX Global Collaborative Network to …
I recently had the privilege of speaking at the Advances in Rheumatology and Technologies Symposium (ARTS), held in Chicago on
🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live – Your must-watch debrief
Early Peripheral SpA: Is it okay to stop treatment sometimes? tammytilley@gm… Mon, 10/27/2025 – 09:52 Spondyloarthritis Dr. Richard Conway reports
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly low https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john…
Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer maj
This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA look https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg
GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in
Catching AxSpA Early: Closing the Diagnostic Gap tammytilley@gm… Mon, 10/27/2025 – 09:20 Spondyloarthritis Labs/Biomarkers Dr. Akhil Sood reports on abstract
Is Low Disease Activity Low Enough? tammytilley@gm… Mon, 10/27/2025 – 09:10 Rheumatoid Arthritis Drs. Jonathan Kay and Joel Kremer discuss
… Rheumatology Convergence, this year taking place in Chicago. Established in 2005, the Evelyn V. Hess Award recognizes a clinical
A small percentage of rheumatology practices (7.1% and 10.1%, respectively) provided care for half of all Medicaid and highly socially
I recently had the privilege of speaking at the Advances in Rheumatology and Technologies Symposium (ARTS), held in Chicago on
Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBes https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john…
Should we be using JAKi more in female SpA patients? drrichardconwa… Mon, 10/27/2025 – 08:45
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults leefam59@gmail.com Mon, 10/27/2025 – 08:30
New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes tammytilley@gm… Mon, 10/27/2025 – 08:15
Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be re https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg
Postmenopausal women using hormone therapy were more likely to develop autoimmune diseases compared with nonusers, research presented at the Annual
Nationwide Study Exposes Thrombosis Burden in SLE. 27 Oct 2025. Rheumatology · View All News. Hospital burden of thrombotic events
Current American College of Rheumatology, European Alliance of Associations for Rheumatology, and Kidney Disease: Improving Global Outcomes …
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce
